Report Library
All Reports
2017 Biomedtracker / Datamonitor Healthcare ADA Planner
May 31, 2017
The American Diabetes Association (ADA) 77th Scientific Sessions will be held in San Diego, CA from 9–13 June 2017.
Cardiovascular outcomes trials (CVOTs) of diabetes drugs will be a big topic at this year's conference. The highlights are previously unreleased CVOT results from SGLT2 inhibitor Invokana's (JNJ, DSKYF, Mitsubishi, PDLI) CANVAS program, which could help confirm a class benefit on CV death, and first conference details from Tresiba's (NVO) DEVOTE, which while not demonstrating superiority on CV events compared to Lantus (SNY), did show a drop in severe hypoglycemia. Other sessions will have new data from previously released CVOTs, as well as cost effectiveness of such newer therapies and implications for guidelines.
There will also be first release of data or first conference details for a number of other drugs, including: oral GLP-1 agonist TTP273 (VTVT), biosimilar insulins SAR342434 (SNY) and MYL-1501D (Mylan, Biocon), ultra-rapid mealtime insulin LY900014 (LLY), SGLT1/2 inhibitor sotagliflozin (SNY, LXRX) in type 1 diabetes, MetAP2 inhibitor ZGN-1061 (ZFGN), and oxyntomodulin analog LY2944876 (OPK, LLY).
We highlight these and other presentations below. For additional posters that are of possible interest, please see those recommended in the accompanying Excel planner.
Full abstracts will be available on Friday 2 June, but will still be embargoed until presentation.
Drugs Highlighted:
If you have already selected presentations on the ADA itinerary planner and would like to format them like our Excel planner, please contact askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
Cardiovascular outcomes trials (CVOTs) of diabetes drugs will be a big topic at this year's conference. The highlights are previously unreleased CVOT results from SGLT2 inhibitor Invokana's (JNJ, DSKYF, Mitsubishi, PDLI) CANVAS program, which could help confirm a class benefit on CV death, and first conference details from Tresiba's (NVO) DEVOTE, which while not demonstrating superiority on CV events compared to Lantus (SNY), did show a drop in severe hypoglycemia. Other sessions will have new data from previously released CVOTs, as well as cost effectiveness of such newer therapies and implications for guidelines.
There will also be first release of data or first conference details for a number of other drugs, including: oral GLP-1 agonist TTP273 (VTVT), biosimilar insulins SAR342434 (SNY) and MYL-1501D (Mylan, Biocon), ultra-rapid mealtime insulin LY900014 (LLY), SGLT1/2 inhibitor sotagliflozin (SNY, LXRX) in type 1 diabetes, MetAP2 inhibitor ZGN-1061 (ZFGN), and oxyntomodulin analog LY2944876 (OPK, LLY).
We highlight these and other presentations below. For additional posters that are of possible interest, please see those recommended in the accompanying Excel planner.
Full abstracts will be available on Friday 2 June, but will still be embargoed until presentation.
Drugs Highlighted:
- Cardiovascular Outcomes Trials (CVOTs) of Diabetes Drugs: Invokana (JNJ, DSKYF, Mitsubishi, PDLI), Jardiance (Boehringer, LLY), Tresiba (NVO), semaglutide (NVO), Victoza (NVO)
- Other SGLT2 Inhibitor Presentations: sotagliflozin (SNY, LXRX), ertugliflozin (MRK, PFE)
- Other GLP-1 Agonist Presentations: TTP273 (VTVT), oral semaglutide (NVO, EMIS)
- Insulins: SAR342434 (SNY), MYL-1501D (MYL, Biocon), LY900014 (LLY), BioChaperone Lispro (Adocia), Toujeo (SNY), Tresiba (NVO), Xultophy (NVO), Diamyd (DMYDY)
- PCSK9 Inhibitors: Praluent (REGN, SNY)
- Other Mechanisms: ZGN-1061 (ZFGN), LY2944876 (OPK, LLY), RG7992 (Roche), Bimagrumab (NVS, MorphoSys), TMG- 123 (Teijin)
If you have already selected presentations on the ADA itinerary planner and would like to format them like our Excel planner, please contact askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: |
Acute Coronary Syndrome (ACS)
Coronary Artery Disease Diabetes Mellitus, Type I Diabetes Mellitus, Type II Diabetic Nephropathy Obesity Percutaneous Coronary Interventions (PCIs) for Stable Angina |
Additional Resources:
- Diabetes CVOTs and Cardiologists Survey
- PCSK9 Inhibitors after FOURIER Survey
- Expected PCSK9 Inhibitor Reimbursement after FOURIER
- 2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ACC Report
- Datamonitor Biosimilars Market Access in the US (2017)
- Diabetes CVOTs Primary Care KOL Interview
- Diabetes CVOTs Survey
- 2016 Biomedtracker / Datamonitor Post-ADA Report